The progression-free survival (PFS) benefit of combination treatment compared with atezolizumab alone was particularly marked in patients with HCC who had high expression of the following biomarkers: VEGFR2 gene (KDR), myeloid, Tregs, and triggering receptor expressed on myeloid cells-1 (TREM-1) (Table 2). Here, KDR is linked to hepatocellular carcinoma.